๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฒ๐˜…๐—ผ๐—ป ๐—ต๐—ฎ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ฝ๐—น๐—ฒ๐—ฎ๐˜€๐˜‚๐—ฟ๐—ฒ ๐—ผ๐—ณ ๐—ฎ๐˜๐˜๐—ฒ๐—ป๐—ฑ๐—ถ๐—ป๐—ด BioBridges Conference ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ ๐—ถ๐—ป ๐—ฃ๐—ฟ๐—ฎ๐—ด๐˜‚๐—ฒ!

From September 26th to 27th, the event brought together professionals in bioequivalence and pharmaceutical development, offering a valuable platform for knowledge-sharing and networking.

Our CEO and EUQPPV,ย Parvinder Punia, together with the team of Pharmexon experts, delivered presentations on critical topics such as โ€œChallenges in Legal Basis Selection for Complex Developmentโ€ and โ€œNational Specificities in OTC Status for Products.โ€

The conference fostered insightful conversations and new connections, and weโ€™re already looking forward to BioBridges 2025! ๐Ÿ’กโœจ

Latest Posts
Expert Regulatory Translation Services for Seamless Compliance

Pharmexonโ€™s expert translation team enhances products, communication, and value for clients by delivering high-quality translations

๐Ÿ“š Strengthening Our Expertise: Product-Specific Guidance

At Pharmexon, we believe in fostering a culture of continuous learning to stay ahead in

Regulatory Intelligence September – October 2024

The Pharmaceutical Industry is incredibly dynamic, with constant updates occurring all through various fields encompassing

๐Ÿšจ Important Update from the European Medicines Agency (EMA) ๐Ÿšจ

This fall a significant EMA update of guideline on Environmental Risk Assessment (ERA) for Medicinal

Pharmexon Company Breakfast

Only a couple of weeks ago, one of Pharmexonโ€™s favorite traditions occurredโ€” the Pharmexon Company